Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran.

Zahra GoudarziFarhad LotfiZhila NajafpourAliAkbar HafeziMarzieh Alizadeh ZakariaKhosro Keshavarz

Published in: BMC urology (2024)

At current prices, adding enzalutamide to pharmaceutical lists represents the cost-effective use of the healthcare resources in Iran for the treatment of metastatic castration-resistant prostate cancer.

Keyphrases

prostate cancer
healthcare
squamous cell carcinoma
small cell lung cancer
radical prostatectomy
combination therapy
social media